Homologous recombination deficiency (HRD) testing can provide crucial diagnostic information, including tBRCAm status, which can be used to personalise the treatment options for patients with newly diagnosed advanced ovarian cancer.1,2
HRD and BRCA tumour testing both analyse tumour tissue and have the same sample requirements. While tumour BRCA testing can identify tBRCA1/2 mutations, HRD testing identifies patients as HRD-positive by detecting BRCA1/2 mutations and measuring genomic instability.1,2
Both results are provided as part of the HRD test report, allowing decisions to be optimised in the patient treatment pathway. Therefore, moving forwards only a HRD test needs to be requested to inform treatment decisions for your patient.1
Based on the outcome of the HRD test, you can consider Lynparza (olaparib) first-line maintenance treatment as an option for our eligible patients, either in combination with bevacizumab or Lynparza monotherapy. Learn more about HRD test results and Lynparza maintenance options.